Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference
Cyclerion Therapeutics announced that its management will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 4:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cyclerion Therapeutics announced that its management will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 4:00 p.m. ET. Investors can request individual meetings through Jefferies. The presentation will be accessible via the Investors & Media section of the Cyclerion website, and an archived replay will be available for 90 days post-event.
Cyclerion is focused on developing treatments to restore cognitive function, with its lead compound CY6463 currently in clinical trials for Alzheimer's Disease and other cognitive impairments.
Details
News Market Reaction – CYCN
The recorded move for CYCN in the trading session of this news was +0.34%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that Company management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:00 p.m. ET. Management will also be available for one-on-one meetings and investors may request a meeting through Jefferies.
The live webcast can be accessed via the Investors & Media section of the Cyclerion website at https://ir.cyclerion.com/news-events/event-calendar. An archived replay of the event will be available on the site for approximately 90 days following the presentation.
About Cyclerion Therapeutics
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion’ is advancing novel, first-in-class, CNS-penetrant, sGC stimulators that modulate a key node in a fundamental CNS signaling pathway. The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases. The most advanced compound, CY6463 has shown rapid improvement in biomarkers associated with cognitive function and is currently in clinical development for Alzheimer's Disease with Vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment Associated with Schizophrenia (CIAS). Cyclerion is also advancing CY3018, a next generation sGC stimulator.
For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).
Investors
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
Media
Amanda Sellers
Verge Scientific Communications
asellers@vergescientific.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.